Details for Patent: 12,734,132
Which drugs does patent 12,734,132 protect, and when does it expire?
Patent 12,734,132 protects DYANAVEL XR 10, DYANAVEL XR 15, DYANAVEL XR 20, and DYANAVEL XR 5, and is included in one NDA.
Drugs Protected by US Patent 12,734,132
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | DYANAVEL XR 10 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-002 | Nov 4, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | ⤷ Start Trial | ||||
| Tris Pharma Inc | DYANAVEL XR 15 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-003 | Nov 4, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | ⤷ Start Trial | ||||
| Tris Pharma Inc | DYANAVEL XR 20 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-004 | Nov 4, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | ⤷ Start Trial | ||||
| Tris Pharma Inc | DYANAVEL XR 5 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-001 | Nov 4, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
